Latest filing published 17 Sept 2026 for Altimmune, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Linda M. Richardson is a declared insider at 2 companies (chief executive); the most frequent names are Intercept Pharmaceuticals, Inc. and Altimmune, Inc. We count 17 filings; the first trade dates from 15 May 2021 and the latest from 16 September 2026.
The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Most recently, on 17 September 2026, the filings show an option exercise in Altimmune, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
17 of 17 declarations